Dongin (Donoven) Kim, Ph.D.
Assistant Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Office College of Pharmacy, CPB 317
Email dongin-kim@ouhsc.edu
Publications & Presentations
- 16. Kim Y, Youn Y S, Oh K T, Kim D, Lee E S. Tumor-Targeting Liposomes with Transient Holes Allowing Intact Rituximab Internally. Biomacromolecules. 2020
17. Kang C, Han P, Lee J S, Lee D, Kim D. Anchor, Spacer, and Ligand-Modified Engineered Exosomes for Trackable Targeted Therapy. Bioconjugate chemistry. 2020; 31 : 2541-2552
18. Yoon S, Kim Y, Youn Y S, Oh K T, Kim D, Lee E S. Transferrin-Conjugated pH-Responsive γ-Cyclodextrin Nanoparticles for Antitumoral Topotecan Delivery. Pharmaceutics. 2020; 12
19. Lee E, Park J, Youn Y S, Oh K T, Kim D, Lee E S. Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis. Biomedicines. 2020; 8
20. Kang M, Tang B, Li J, Zhou Z, Liu K, Wang R, Jiang Z, Bi F, Patrick D, Kim D, Mitra A K, Yang-Hartwich Y. Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA. Molecular cancer. 2020; 19 : 143
Grants
- 1. Extracellular Vesicle-Based Intraocular Therapy Combined with Active Targeting of Ocular Neovascularization. NEI. Start Date: 2024. End Date: 2029.
2. MiPEP133, a New Tumor Suppressor for Ovarian Cancer. American Cancer Society. Start Date: 2024. End Date: 2027.
3. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
4. Lymphatics and lymphangiogenesis in kidney function and inflammation. NIH. Start Date: 2019. End Date: 2024.
5. Extracellular Vesicle Therapy for Diabetic Retinopathy. NEI. Start Date: 2023. End Date: 2024.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results